ArticleInsights into imaging2021
Pneumonic-type lung adenocarcinoma with different ranges exhibiting different clinical, imaging, and pathological characteristics.
Article in Insights into imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- Drug-Induced Lung Injury Masking Lung Adenocarcinoma.Respirology case reports · 2026Article
- Quantitative peri-lesional densitometry mapping via thin-slice volume rendering enhances differentiation of pneumonic-type lung cancer and inflammatory pneumonia.Frontiers in oncology · 2026Article
- Bilateral pulmonary cavitary mucinous adenocarcinoma in an immunocompetent patient: a case report and literature review.BMC pulmonary medicine · 2025Review
- Diffuse Pneumonic Type Lepidic Adenocarcinoma (DP-LPA).Respirology case reports · 2025Article
- Radiological Features of Primary Pulmonary Invasive Mucinous Adenocarcinoma Based on 312 Consecutive Patients.The clinical respiratory journal · 2024Article
- The More You See, the More Confusion: Two Cases of Pneumonia With Confusing Imaging Findings of Adenocarcinoma.Cureus · 2024Article
- Pneumonic-type lung adenocarcinoma with KRAS G12V mutation and sustained response to Afatinib.Pneumonia (Nathan Qld.) · 2024Article
- Radiological and clinical features of large consolidative-type pulmonary invasive mucinous adenocarcinoma.The clinical respiratory journal · 2024Article
- Lung adenocarcinoma presenting as acute hypoxemic respiratory failure.Respiratory medicine case reports · 2024Article
- Clinicopathological and computed tomography features associated with recurrence-free survival of patients with small-sized peripheral invasive lung adenocarcinoma after sublobectomy.Quantitative imaging in medicine and surgery · 2023Article
- Differentiation of localized pneumonic-type lung adenocarcinoma from localized pulmonary inflammatory lesion based on clinical data and multi-slice spiral computed tomography imaging features.Translational cancer research · 2023Article
- Pneumonic-type invasive mucinous adenocarcinoma and infectious pneumonia: clinical and CT imaging analysis from multiple centers.BMC pulmonary medicine · 2022Article
- State of the Art: Lung Cancer Staging Using Updated Imaging Modalities.Bioengineering (Basel, Switzerland) · 2022Review
- Differential diagnosis of localized pneumonic-type lung adenocarcinoma and pulmonary inflammatory lesion.Insights into imaging · 2022Article
- Combined model of radiomics and clinical features for differentiating pneumonic-type mucinous adenocarcinoma from lobar pneumonia: An exploratory study.Frontiers in endocrinology · 2022Article
- Pneumonic-type lung adenocarcinoma presenting as non-obstructive lobar pneumonia.Lung India : official organ of Indian Chest SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundPneumonic-type lung adenocarcinoma (PLADC) with different ranges might exhibit different imaging and clinicopathological features. This study divided PLADC into localized PLADC (L-PLADC) and diffuse PLADC (D-PLADC) based on imaging and aimed to clarify the differences in clinical, imaging, and pathologic characteristics between the two new subtypes.
resultsThe data of 131 patients with L-PLADC and 117 patients with D-PLADC who were pathologically confirmed and underwent chest computed tomography (CT) at our institute from December 2014 to December 2020 were retrospectively collected. Patients with L-PLADC were predominantly female, non-smokers, and without respiratory symptoms and elevated white blood cell count and C-reactive protein level, whereas those with D-PLADC were predominantly male, smokers, and had respiratory symptoms and elevated white blood cell count and C-reactive protein level (all p < 0.05). Pleural retraction was more common in L-PLADC, whereas interlobular fissure bulging, hypodense sign, air space, CT angiogram sign, coexisting nodules, pleural effusion, and lymphadenopathy were more frequent in D-PLADC (all p < 0.001). Among the 129 patients with surgically resected PLADC, the most common histological subtype of L-PLADC was acinar-predominant growth pattern (76.7%, 79/103), whereas that of D-PLADC was invasive mucinous adenocarcinoma (80.8%, 21/26). Among the 136 patients with EGFR mutation status, L-PLADC had a significantly higher EGFR mutation rate than D-PLADC (p < 0.001).
conclusionsL-PLADC and D-PLADC have different clinical, imaging, and pathological characteristics. This new imaging-based classification may help improve our understanding of PLADC and develop personalized treatment plans, with concomitant implications for patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.